{"url_path":"/sec/aibt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1763329/0001096906-26-000922-index.html","accession_number":"0001096906-26-000922","cik":"0001763329","ticker":"AIBT","issuer_name":"AIBOTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763329/0001096906-26-000922-index.html","primary_entity_key":"0001763329","primary_entity_name":"AIBOTICS, INC."},"word_count":107,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n\n \n\n**Description**\n\n \n\n \n\n \n\n31.01\n\n \n\n[Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14](tpia_ex31z1.htm)\n\n \n\n32.1\n\n \n\n[Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](tpia_ex32z1.htm)\n\n20\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n**AIBiotics Therapies, Inc.**\n\n \n\n \n\n*Date: June 8, 2026*\n\nBy:\n\n*/s/ Ben Kaplan*\n\n \n\nName: \n\nBen Kaplan\n\n \n\nTitle:\n\n*Chief Executive Officer and*\n*Principal Accounting Officer*\n\n21"}